Real-world experience shows gilteritinib improves survival in FLT3-mutated AML after transplantation, suggesting its efficacy as maintenance therapy.
Key Points
To evaluate the effectiveness of gilteritinib maintenance therapy in patients with relapsed/refractory acute myeloid leukemia after allogeneic transplantation.
Patients with FLT3-mutated relapsed/refractory AML received gilteritinib before transplantation.
Posttransplant maintenance was offered to those achieving engraftment without significant acute graft-versus-host disease.
Follow-up duration was a median of 46.2 months.
The cohort achieved a complete response rate of 76.2%.
Gilteritinib maintenance therapy was associated with longer relapse-free and overall survival.
There was a significantly lower 1-year cumulative incidence of relapse.